Conference Call to Be Held May 19 at 10:00 a.m. PDT; Phase 3 Confirmatory Study Data On-Track for Second Quarter

By The Associated Press Monday, May 16, 2024

Get daily Bioscience Technology industry top stories and headlines - Sign up now!

newsvine diigo google
slashdot
Share
Loading...

http://www.titanpharm.com/ () —

Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the first quarter ended March 31, 2011.

Total revenues for the first quarter of 2011 were $0.9 million, consisting of $0.7 million in royalties on net sales of Fanapt@ and $0.2 million in grant revenues from the National Institutes of Health (NIH) in support of the ongoing confirmatory Phase 3 clinical study of Probuphine and the SBIR grant for Titan's proprietary ProNeura drug delivery technology.

Total operating expenses for the first quarter of 2011 were $4.5 million, compared with $2.6 million for the first quarter of 2010. The year-over-year increase in expenses resulted primarily from an increase of approximately $2.0 million in research and development (R&D) expense related to the Phase 3 clinical study of Probuphine currently in progress, which was offset in part by a decrease in general and administrative (G&A) expenses of $0.1 million.

Net loss for the first quarter of 2011 was $4.5 million or $0.08 per share compared with a net loss of $0.3 million or $0.01 per share for the first quarter of 2010.

At March 31, 2011, we had cash and cash equivalents of approximately $0.8 million. On April 5, 2011, we completed our transactions with entities affiliated with Deerfield Management for a loan of $20.0 million to the company. We used a portion of the proceeds received to repay the outstanding debt of $7.7 million to Oxford Finance Corporation and also paid a facility fee to Deerfield of $0.5 million. With the recently completed financing and the royalty revenues expected from the sales of Fanapt, we believe that we have sufficient cash resources to fund operations into the first quarter of 2012.

"We have continued to make excellent progress with the confirmatory Phase 3 study of Probuphine and are on target to announce top-line results before the end of the second quarter," said Sunil Bhonsle, President of Titan Pharmaceuticals. "Completion of the recent financing with Deerfield provides the resources to continue the clinical and manufacturing development of Probuphine, and the six month patient re-treatment study is progressing smoothly and will provide important safety data on patients treated for up to one year by the end of this year," he noted.

"This has been an important time period for the Company as we prepare for the upcoming events, and the board is in full support of the ongoing efforts," said Marc Rubin, M.D., Executive Chairman of Titan Pharmaceuticals. "Dr. Kate Beebe has provided outstanding leadership for the Probuphine clinical development program, and is highly respected by both the physician and patient communities. In recognition of Dr. Beebe's many important contributions, the board recently appointed her to the position of Executive Vice President and Chief Development Officer. We congratulate her as we continue with the important task of seeking partners for the future commercialization of Probuphine, and the possible opportunity to offer a meaningful therapeutic alternative to patients with the disease of opioid addiction," he added.

First Quarter 2011 Additional Financial Results

R&D expenses for the first quarter of 2011 were $3.7 million, compared with $1.7 million in the comparable period of 2010. The increase in R&D expense reflects the costs of conducting the Phase 3 clinical study of Probuphine and includes approximately $2.9 million of external expenses such as clinical research organization charges, investigator and patient-related clinical site expenses, and other associated costs. The remaining R&D expenses reflect internal operating costs such as personnel-related expenses, meeting and travel expenses and allocation of facility and corporate costs.

G&A expenses for the first quarter of 2011 decreased to $0.8 million from $0.9 million in the comparable period of 2010 primarily due to decreases in consulting and professional fees.

Probuphine: Recent and Upcoming Events

Probuphine is a novel formulation of buprenorphine that is capable of maintaining a stable, round the clock level of medicine in patients for six months following a single treatment. It is in Phase 3 development for the treatment of opioid addiction and Titan is currently conducting a confirmatory Phase 3 clinical study in the U.S. that is partially funded through a two-year $7.6 million NIH grant being administered by the National Institute on Drug Abuse (NIDA). Recent and upcoming events include the following:

-- Last patient treatment and follow-up in the confirmatory Phase 3 efficacy and safety study of Probuphine for the treatment of opioid addiction is complete, and top-line results are expected before the end of June 2011. -- Patient enrollment is complete in the Phase 3 open label study for the re-treatment of patients who completed the controlled confirmatory study, and results of this study will be available before year end 2011. -- A pre-NDA meeting with the Food and Drug Administration to review clinical and other support data is targeted for late in the third quarter of this year. -- Upcoming scientific presentations: - NIDA International Forum: Building International Collaborative Research on Drug Abuse, Hollywood, FL, June 2011 - International Society of Addiction Medicine annual meeting, Oslo, Norway, September 2011 - American Academy of Addiction Psychiatry, Scottsdale, AZ, December 2011

Conference Call

Titan management will host a live call and webcast on Thursday, May 19, 2011 at 10:00 a.m. PDT (1:00 p.m. EDT) to discuss our first quarter 2011 results and current corporate developments. The live webcast of the call may be accessed by visiting our website at www.titanpharm.com (http://www.titanpharm.com) . The call can also be accessed by dialing 1-800-289-0508 Participant code: 1991632 five minutes prior to the start time. A replay of the call will be available on our website approximately two hours after completion of the call and will be archived for two weeks.

About Titan Pharmaceuticals

For information concerning Titan Pharmaceuticals, Inc., please visit the Company's website at www.titanpharm.com (http://www.titanpharm.com) .

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

TITAN PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amount) Three Months Ended March 31, ------------------------ 2011 2010 ----------- ----------- (unaudited) Revenue: Royalty revenues $ 716 $ 1,653 Grant revenue 232 761 License revenue - 11 ----------- ----------- Total revenue 948 2,425 Operating expenses: Research and development 3,738 1,670 General and administrative 793 935 ----------- ----------- Total operating expenses 4,531 2,605 ----------- ----------- Loss from operations (3,583) (180) Other expense (929) (125) ----------- ----------- Net loss $ (4,512) $ (305) Basic and diluted net loss per share $ (0.08) $ (0.01) Weighted average shares used in computing basic and diluted net loss per share 59,248 59,248 CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) March 31, December 31, 2011 2010 ----------- ----------- (unaudited) (Note A) Assets Cash and cash equivalents $ 800 $ 3,180 Receivables 2,155 1,225 Prepaid expenses and other current assets 220 294 ----------- ----------- Total current assets 3,175 4,699 Furniture and equipment, net 43 53 ----------- ----------- $ 3,218 $ 4,752 Liabilities and Stockholders' Equity Current liabilities $ 8,714 $ 5,405 Long-term debt 4,930 5,400 Stockholders' deficit (10,426) (6,053) ----------- ----------- $ 3,218 $ 4,752 Note A: The year end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America.

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Bringing the Cell Image into Focus

Nov 2 2010

Improvements in transmission electron microscope (TEM) technology increase the power of this imaging tool for the study of cell biology.

Finding a Cure for Spinal Cord Injury with On-Demand LIMS

Oct 25 2010

The Miami Project to Cure Paralysis finds an on-demand laboratory information management system (LIMS) helps to accelerate discovery in its HCS projects.

Saving Cells: Image Processing for Improved Viability, Part II: Iterative Deconvolution

Oct 25 2010

3D light microscopy and deconvolution provide a means to investigate 3D structure, providing near-confocal quality images without the temporal requirements or potentially damaging phototoxicity associated with other 3D imaging technologies. This article is Part II in a series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part I focused on spectral unmixing.

Saving Cells: Image Processing for Improved Viability

Sep 22 2010

This article is Part I of a two-part series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part II will focus on deconvolution.

Evaluation of a New Nano-Type UV-Vis Spectrophotometer

Mar 3

Analysis of one- to four-microliter size samples for nucleic acids has become routine in many life science laboratories. However, until now, available instruments require considerable manipulation of the instrument and sample; some require manually recording the data. The user must typically lower and raise the arm manually, then wipe the sample manually from the target after each analysis. And fiberoptics used in some of these instruments are subject to deterioration.

Production of Recombinant Proteins and Monoclonal Antibodies in Hollow Fiber Bioreactors

Jan 25

While well-understood, robust and convenient, classical batch-style 2-D culture on non-porous supports or 3-D suspension culture in other devices are really not very biologically relevant models. Cell culture conditions can affect the quality of the antibody or protein produced.

Selecting Robots for Use in Drug Discovery and Testing

Dec 6 2010

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Sep 13 2010

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11 2010

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2 2010

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1 2010

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Introduction to placebo effects in medicine: mechanisms and clinical implications.

2 hours ago

The field of placebo research has made considerable progress in the last years and it has become a major focus of interest. We know now that the placebo effect is a real neurobiological phenomenon and that the brain's 'inner pharmacy' is a critical determinant...

Seed and grow: a two-step model for nuclear body biogenesis.

3 hours ago

Nuclear bodies are dynamic structures that form at sites of specific activities associated with gene expression and genome maintenance. A paper in this issue (White et al. 2011. J. Cell Biol. doi: 10.1083/jcb.201012077) highlights key features of nuclear body...

Richard G.W. Anderson (1940-2011) and the birth of receptor-mediated endocytosis.

3 hours ago

On March 19, 2011, the discipline of cell biology lost a creative force with the passing of Richard G.W. Anderson, Professor and Chairman of the Department of Cell Biology at the University of Texas Southwestern Medical School. An unabashed chauvinist for cell...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11 2010

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Top Stories and Headlines
EVERYDAY!

FREE Email Newsletter

Information: